作者
Ralf Metzger, Cynthia Gail Leichman, Kathleen D Danenberg, Peter V Danenberg, Heinz-Josef Lenz, Kazuhiko Hayashi, Susan Groshen, Dennis Salonga, Hartley Cohen, Loren Laine, Peter Crookes, Howard Silberman, Joaquina Baranda, Brahma Konda, Lawrence Leichman
发表日期
1998/1
期刊
Journal of Clinical Oncology
卷号
16
期号
1
页码范围
309-316
简介
PURPOSE
We have previously shown that relative thymidylate synthase (TS) mRNA levels in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are inversely associated with response and survival. This is a presumed function of TS as a target for 5-FU activity. We now test the hypotheses that the relative mRNA level of the excision repair cross-complementing (ERCC1) gene is inversely associated with response and survival as an independent function of cisplatin efficacy.
PATIENTS AND METHODS
Patients had intact, untreated, primary gastric adenocarcinoma cancer and were evaluated for eligibility on a preoperative cisplatin infusion-5-FU protocol. cDNA, derived from primary gastric tumors before chemotherapy, was used to determine ERCC1 mRNA levels, expressed as the ratio of polymerase chain reaction (PCR) product of the ERCC1 gene and the beta-actin gene.
RESULTS
The …
引用总数
学术搜索中的文章
R Metzger, CG Leichman, KD Danenberg… - Journal of Clinical Oncology, 1998
